BEVERLY, Mass. and TORONTO, July 22, 2024 (GLOBE NEWSWIRE) — Hamilton Thorne Ltd (TSX: HTL) (“Hamilton Thorne” or the “Company”), a leading provider of precision instruments, consumables, software, and services to the Assisted Reproductive Technologies (“ART”), research, and the cell biology space, today announced that it has entered into a definitive arrangement agreement dated July 21, 2024 (the “Arrangement Agreement”) with an acquisition vehicle (the “Purchaser”) managed by Astorg, a leading private equity firm with an extensive track record in global healthcare investments, whereby the Purchaser has agreed to acquire 100% of the issued and outstanding common shares (the “Company Shares”) of the Company (the “Transaction”).
BEVERLY, Mass. and TORONTO, July 22, 2024 (GLOBE NEWSWIRE) — Hamilton Thorne Ltd (TSX: HTL) (“Hamilton Thorne” or the “Company”), a leading provider of precision instruments, consumables, software, and services to the Assisted Reproductive Technologies (“ART”), research, and the cell biology space, today announced that it has entered into a definitive arrangement agreement dated July 21, 2024 (the “Arrangement Agreement”) with an acquisition vehicle (the “Purchaser”) managed by Astorg, a leading private equity firm with an extensive track record in global healthcare investments, whereby the Purchaser has agreed to acquire 100% of the issued and outstanding common shares (the “Company Shares”) of the Company (the “Transaction”). Read MoreTSX:HTL, CA4078911001
GlobeNewswire – Mergers And Acquisitions
